<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00366444</url>
  </required_header>
  <id_info>
    <org_study_id>XP21L-301</org_study_id>
    <nct_id>NCT00366444</nct_id>
  </id_info>
  <brief_title>Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery</brief_title>
  <official_title>Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xanodyne Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xanodyne Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      A multicenter study to evaluate the analgesic efficacy of XP21L in subjects with pain
      following bunionectomy surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy</measure>
    <time_frame>Over 48 hours after bunionectomy</time_frame>
    <description>Pain intensity scores were measured using an 11-point numerical pain rating scale (NPRS) with 0=no pain to 10=worst possible pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Perceptible Pain Relief on Day 1</measure>
    <time_frame>8 hours post single dose</time_frame>
    <description>Times to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Onset of Pain Relief in Patients With Perceptible Pain Relief on Day 1</measure>
    <time_frame>8 hours post single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Meaningful Pain Relief on Day 1</measure>
    <time_frame>8 hours post single dose</time_frame>
    <description>Times to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Onset of Pain Relief in Patients With Meaningful Pain Relief on Day 1</measure>
    <time_frame>8 hours post single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief (TOTPAR) Scores 8 Hours Post Initial Dose of Study Drug</measure>
    <time_frame>8 hours post single dose</time_frame>
    <description>Pain relief was rated using a 5-point categorial scale (0=none, 1=a little, 2=some, 3=a lot, and 4=complete) at time of dose (time=0) and over 15 time points afterwards (10, 15, 20, 30, 45, and 60 minutes and at 1.5, 2, 2.5, 3, 4, 5, 6, 7, and 8 hours after the initial dose on Day 1 or until time of re-medication). A score of 0 across all time points would be the lowest (worst) and a score of 60 (4 X 15 time points) would be the highest (best) possible score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least 30% Reduction in Pain Intensity After First Dose of Study Drug</measure>
    <time_frame>8 hours post single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of at Least 30% Reduction in Pain Intensity After First Dose of Study Drug</measure>
    <time_frame>8 hours post single dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Required Rescue Medication on Day 1</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Required Rescue Medication on Day 2</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Required Rescue Medication on Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>Day 3 data reflect the use of rescue medication only up to the time of discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diclofenac potassium (XP21L)</intervention_name>
    <description>25 mg every 6 hours</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zipsor Liquid Filled Capsule</other_name>
    <other_name>XP21L</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo every 6 hours</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years of age

          -  Have undergone bunionectomy surgery

          -  Have achieved adequate post-surgical pain

        Exclusion Criteria:

          -  Confounding medical conditions which preclude study participation

          -  Participated in a study of another investigational drug or device within 30 days prior
             to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92869</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <zip>21117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>15946</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.zipsor.com/</url>
  </link>
  <results_reference>
    <citation>Riff DS, Duckor S, Gottlieb I, Diamond E, Soulier S, Raymond G, Boesing SE. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days. Clin Ther. 2009 Oct;31(10):2072-85. doi: 10.1016/j.clinthera.2009.09.011.</citation>
    <PMID>19922878</PMID>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2006</study_first_submitted>
  <study_first_submitted_qc>August 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2006</study_first_posted>
  <results_first_submitted>March 22, 2010</results_first_submitted>
  <results_first_submitted_qc>April 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 13, 2011</results_first_posted>
  <last_update_submitted>April 12, 2011</last_update_submitted>
  <last_update_submitted_qc>April 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Gary Shangold, MD / Chief Medical Officer</name_title>
    <organization>Xanodyne Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Bunionectomy</keyword>
  <keyword>Bunion surgery</keyword>
  <keyword>Post-operative pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zipsor (Diclofenac Potassium) Liquid Filled Capsule</title>
          <description>25 mg capsule, every 6 hours</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Oral placebo capsule, every 6 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zipsor (Diclofenac Potassium) Liquid Filled Capsule</title>
          <description>25 mg capsule, every 6 hours</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Oral placebo capsule, every 6 hours</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="201"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="11"/>
                    <measurement group_id="B2" value="45" spread="12"/>
                    <measurement group_id="B3" value="45" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline pain score</title>
          <description>Pain intensity scores were measured using an 11-point numerical pain rating scale (NPRS) with 0=no pain to 10=worst possible pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9" spread="1.7"/>
                    <measurement group_id="B2" value="7.3" spread="1.9"/>
                    <measurement group_id="B3" value="7.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy</title>
        <description>Pain intensity scores were measured using an 11-point numerical pain rating scale (NPRS) with 0=no pain to 10=worst possible pain</description>
        <time_frame>Over 48 hours after bunionectomy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zipsor (Diclofenac Potassium) Liquid Filled Capsule</title>
            <description>25 mg capsule, every 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo capsule, every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Average Numeric Pain Rating Score (NPRS) Over 48 Hours After Bunionectomy</title>
          <description>Pain intensity scores were measured using an 11-point numerical pain rating scale (NPRS) with 0=no pain to 10=worst possible pain</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.0"/>
                    <measurement group_id="O2" value="5.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Perceptible Pain Relief on Day 1</title>
        <description>Times to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method.</description>
        <time_frame>8 hours post single dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zipsor (Diclofenac Potassium) Liquid Filled Capsule</title>
            <description>25 mg capsule, every 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo capsule, every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Perceptible Pain Relief on Day 1</title>
          <description>Times to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Onset of Pain Relief in Patients With Perceptible Pain Relief on Day 1</title>
        <time_frame>8 hours post single dose</time_frame>
        <population>Number of participants analyzed includes only the number of participants with perceptible pain relief on Day 1 (see previous Outcome Measure #2)</population>
        <group_list>
          <group group_id="O1">
            <title>Zipsor (Diclofenac Potassium) Liquid Filled Capsule</title>
            <description>25 mg capsule, every 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo capsule, every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Onset of Pain Relief in Patients With Perceptible Pain Relief on Day 1</title>
          <population>Number of participants analyzed includes only the number of participants with perceptible pain relief on Day 1 (see previous Outcome Measure #2)</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" lower_limit="18.6" upper_limit="31.3"/>
                    <measurement group_id="O2" value="22.2" lower_limit="16.6" upper_limit="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Meaningful Pain Relief on Day 1</title>
        <description>Times to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method.</description>
        <time_frame>8 hours post single dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zipsor (Diclofenac Potassium) Liquid Filled Capsule</title>
            <description>25 mg capsule, every 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo capsule, every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Meaningful Pain Relief on Day 1</title>
          <description>Times to onset of Perceptible and Meaningful Relief were determined using the double-stopwatch method.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Onset of Pain Relief in Patients With Meaningful Pain Relief on Day 1</title>
        <time_frame>8 hours post single dose</time_frame>
        <population>Number of participants analyzed includes only the number of participants with meaningful pain relief on Day 1 (see previous outcome measure, #4).
Number of patients in the placebo group is intentionally blank as the data was not calculable since less than 50% of the patients reported meaningful relief (ie, median cannot be calculated).</population>
        <group_list>
          <group group_id="O1">
            <title>Zipsor (Diclofenac Potassium) Liquid Filled Capsule</title>
            <description>25 mg capsule, every 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo capsule, every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Onset of Pain Relief in Patients With Meaningful Pain Relief on Day 1</title>
          <population>Number of participants analyzed includes only the number of participants with meaningful pain relief on Day 1 (see previous outcome measure, #4).
Number of patients in the placebo group is intentionally blank as the data was not calculable since less than 50% of the patients reported meaningful relief (ie, median cannot be calculated).</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2" lower_limit="61.2" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Pain Relief (TOTPAR) Scores 8 Hours Post Initial Dose of Study Drug</title>
        <description>Pain relief was rated using a 5-point categorial scale (0=none, 1=a little, 2=some, 3=a lot, and 4=complete) at time of dose (time=0) and over 15 time points afterwards (10, 15, 20, 30, 45, and 60 minutes and at 1.5, 2, 2.5, 3, 4, 5, 6, 7, and 8 hours after the initial dose on Day 1 or until time of re-medication). A score of 0 across all time points would be the lowest (worst) and a score of 60 (4 X 15 time points) would be the highest (best) possible score.</description>
        <time_frame>8 hours post single dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zipsor (Diclofenac Potassium) Liquid Filled Capsule</title>
            <description>25 mg capsule, every 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo capsule, every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Total Pain Relief (TOTPAR) Scores 8 Hours Post Initial Dose of Study Drug</title>
          <description>Pain relief was rated using a 5-point categorial scale (0=none, 1=a little, 2=some, 3=a lot, and 4=complete) at time of dose (time=0) and over 15 time points afterwards (10, 15, 20, 30, 45, and 60 minutes and at 1.5, 2, 2.5, 3, 4, 5, 6, 7, and 8 hours after the initial dose on Day 1 or until time of re-medication). A score of 0 across all time points would be the lowest (worst) and a score of 60 (4 X 15 time points) would be the highest (best) possible score.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="9.3"/>
                    <measurement group_id="O2" value="2.6" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least 30% Reduction in Pain Intensity After First Dose of Study Drug</title>
        <time_frame>8 hours post single dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zipsor (Diclofenac Potassium) Liquid Filled Capsule</title>
            <description>25 mg capsule, every 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo capsule, every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least 30% Reduction in Pain Intensity After First Dose of Study Drug</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of at Least 30% Reduction in Pain Intensity After First Dose of Study Drug</title>
        <time_frame>8 hours post single dose</time_frame>
        <population>Number of participants analyzed includes only the number of participants with at least a 30% reduction in pain intensity after the 1st dose (see previous outcome measure, #7).
Number of placebo patients is intentionally blank as the data (eg., upper CI) was not calculable.</population>
        <group_list>
          <group group_id="O1">
            <title>Zipsor (Diclofenac Potassium) Liquid Filled Capsule</title>
            <description>25 mg capsule, every 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo capsule, every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of at Least 30% Reduction in Pain Intensity After First Dose of Study Drug</title>
          <population>Number of participants analyzed includes only the number of participants with at least a 30% reduction in pain intensity after the 1st dose (see previous outcome measure, #7).
Number of placebo patients is intentionally blank as the data (eg., upper CI) was not calculable.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="45" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Required Rescue Medication on Day 1</title>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zipsor (Diclofenac Potassium) Liquid Filled Capsule</title>
            <description>25 mg capsule, every 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo capsule, every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Required Rescue Medication on Day 1</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Required Rescue Medication on Day 2</title>
        <time_frame>Day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zipsor (Diclofenac Potassium) Liquid Filled Capsule</title>
            <description>25 mg capsule, every 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo capsule, every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Required Rescue Medication on Day 2</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Required Rescue Medication on Day 3</title>
        <description>Day 3 data reflect the use of rescue medication only up to the time of discharge</description>
        <time_frame>Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zipsor (Diclofenac Potassium) Liquid Filled Capsule</title>
            <description>25 mg capsule, every 6 hours</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Oral placebo capsule, every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Required Rescue Medication on Day 3</title>
          <description>Day 3 data reflect the use of rescue medication only up to the time of discharge</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Zipsor (Diclofenac Potassium) Liquid Filled Capsule</title>
          <description>25 mg capsule, every 6 hours</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Oral placebo capsule, every 6 hours</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Superficial cellulitis of the left knee</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body Temperature Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steve Boesing</name_or_title>
      <organization>Xanodyne Pharmaceuticals, Inc.</organization>
      <phone>1-877-926-6396</phone>
      <email>clinical-trials@xanodyne.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

